Dr Wasif Ullah Khan Marwat

25/12/2025

01/12/2025

Denmark's insulin patch eliminated daily injections, but pharmaceutical companies delay US launch

Danish endocrinologists developed a painless skin patch that automatically delivers insulin through microneedles, eliminating the need for daily injections. Diabetic patients maintain perfect blood sugar control without needles or pumps.

The smart patch measures blood glucose continuously through skin sensors and releases precisely calibrated insulin doses via dissolving microneedles smaller than human hair. Users replace patches weekly like bandages—no painful injections, no pump equipment, no constant monitoring. Clinical trials showed better glucose control than traditional insulin therapy with 99% patient satisfaction.

Pharmaceutical companies delayed US market entry by filing competing patents, challenging FDA applications, and lobbying for restrictive regulations. The patch threatens $35 billion annual US insulin sales and $10 billion glucose monitoring device market. Companies profit from daily insulin sales and disposable supplies, making a convenient weekly patch financially threatening to their business model.

Over 8 million Americans inject insulin daily—many missing doses due to needle fear or inconvenience, causing dangerous blood sugar fluctuations. Danish diabetics enjoy pain-free control while Americans wait for corporate legal battles to resolve. The better technology exists but profit protection delays patient access by years.

Should pharmaceutical profits determine when Americans access painless insulin delivery?

Source: Diabetes Care, University of Copenhagen, 2025

16/11/2025

"Thrilled to share that our manuscript, "Perceptions of AI-Driven role replacement among diagnostic specialists in Pakistan: A Qualitative Study," has been accepted for publication by ISIR Publisher! 📚👏

I want to extend my gratitude to my co-authors and team for their hard work and dedication. Special thanks to the reviewers for their valuable feedback, which has helped improve our study.

This research explores the perceptions of AI-driven role replacement among diagnostic specialists in Pakistan, shedding light on the evolving landscape of healthcare and technology. I'm excited to share our findings with the community and contribute to the ongoing conversation on AI in healthcare.

Stay tuned for the publication! "

08/11/2025

"Discover the potential of Intradiscal Condoliase Injections in treating lumbar disc herniation! 🚀 This minimally invasive therapy offers durable pain relief with a single outpatient procedure. Read the editorial in the Northwest Journal of Medical Sciences to learn more about its efficacy, safety, and cost-effectiveness compared to surgery.

Link:
https://lnkd.in/gXVtE6VS

"

This link will take you to a page that’s not on LinkedIn

06/11/2025

🌍 Grateful and Honored! 🙌

I am pleased to share that I have received my Certificate of Participation in the UNESCO Youth Hackathon 2025, organized by the Media and Information Literacy and Digital Competencies (MIL) Team, UNESCO – Paris.

Participating in this global initiative was an enriching experience that allowed me to:
• Collaborate with talented youth from around the world 🤝
• Learn about Media and Information Literacy in the digital age 💡
• Contribute to discussions and ideas that promote informed, safe, and responsible online engagement 🌐

A heartfelt thank you to UNESCO for this amazing opportunity. I look forward to continuing my journey in promoting media literacy, digital responsibility, and positive social impact.

Here’s to more learning, collaboration, and meaningful contributions ahead! ✨

18/10/2025

اینٹی بائیوٹکس کا غلط استعمال

اینٹی بائیوٹکس کا غلط استعمال اس وقت ہوتا ہے جب انہیں ضرورت کے بغیر، غلط مقدار میں، یا ادھورے کورس کی صورت میں استعمال کیا جاتا ہے۔ اس کے علاوہ وائرل بیماریوں جیسے نزلہ، زکام یا فلو میں اینٹی بائیوٹکس کا استعمال بھی غلط استعمال میں شامل ہے۔ بعض اوقات ڈاکٹرز کی جانب سے زیادہ تجویز کرنا یا خود سے ادویات استعمال کرنا بھی اس مسئلے کو بڑھاتا ہے۔

غلط استعمال کے نقصانات
• مزاحمت (Antibiotic Resistance): جراثیم اینٹی بائیوٹکس کے خلاف مزاحم ہو جاتے ہیں اور علاج مشکل ہو جاتا ہے۔
• علاج کی ناکامی: عام ادویات اثر کرنا چھوڑ دیتی ہیں۔
• اخراجات میں اضافہ: لمبا علاج اور مہنگی ادویات کی ضرورت پڑتی ہے۔
• مضر اثرات: الرجی، دست اور بعض اوقات جگر یا گردوں کو نقصان پہنچ سکتا ہے۔

بچاؤ کے طریقے
• اینٹی بائیوٹکس صرف مستند ڈاکٹر کے مشورے سے استعمال کریں۔
• دوا کا مکمل کورس لازمی مکمل کریں چاہے حالت بہتر ہو جائے۔
• خود علاجی (Self-medication) اور دوسروں کی دوا استعمال کرنے سے گریز کریں۔
• عوامی آگاہی اور ذمہ دارانہ نسخہ نویسی کو فروغ دیں۔

11/10/2025

In 1994, Masahiro Hara created the QR code, a revolutionary upgrade to barcodes, capable of storing 100 times more data, scanning from any angle, and surviving damage. Instead of profiting, he and Denso Wave released it freely, enabling global use, from mobile payments to menus, showcasing innovation paired with generosity.

10/10/2025

🌟 Alhamdulillah! Excited to Share a Milestone 🌟

My original research article titled
“Mortality Rates and Age-Based Analysis of Ischemic Stroke in Peshawar: A Comparative Study between Urban and Rural Populations”
has now been officially published online in the Global Academic Journal of Medical Sciences.

🔬 This study highlights critical disparities in stroke outcomes between urban and rural populations of Peshawar, emphasizing the urgent need to strengthen rural healthcare access and stroke management services.

📌 Journal: Global Academic Journal of Medical Sciences
📎 DOI: https://doi.org/10.36348/gajms.2025.v07i05.005
🌍 Available at: www.gajrc.com

It was an honor to lead this work along with my dedicated co-authors.

✨ Looking forward to contributing further to public health research and evidence-based policy for underserved populations.

Remember: Early recognition and timely intervention in stroke can save lives — “Time is Brain!”

March 26, 2025 Trends and Gender Patterns of Expanded Program on Immunization (EPI) Vaccination among Children in Dhaka, Bangladesh Shanta Saha, Dr. Md Alahi Khandaker, Dr. Avijt Sharma, Md. Rafiqul Islam Glob Acad J Med Sci, 2025; 7(2): 66-73 DOI : https://doi.org/10.36348/gajms.2025.v07i02.0...

03/10/2025

Alhamdulillah! I am humbled and delighted to share that my letter to the editor, “In Reply: Impact of Respiratory Syncytial Virus Prevention in Infancy on Prevalence of Asthma Among Native American Children,” has been published in the internationally renowned Pediatric Infectious Disease Journal (PIDJ). This critique highlights important considerations regarding the long-term impact of RSV prevention on childhood asthma prevalence, particularly in vulnerable populations. It emphasizes the need for larger studies, standardized outcome measures, and extended follow-up to better understand RSV’s role in asthma development.

The Pediatric Infectious Disease Journal (PIDJ), published by Wolters Kluwer Health, Inc., is a globally recognized and high-impact journal in the field of pediatric infectious diseases. It has the ISSN 0891-3668 and is indexed in PubMed, MEDLINE, Scopus, and other major scientific databases, making it one of the leading and most respected platforms for pediatric research.

15/08/2025

What does Evidence level in medical literature means like level 1, 2 etc ?

In medical literature, levels of evidence basically rank the strength and reliability of research. This hierarchy helps doctors and researchers decide how much trust to put in a study when applying it to patient care.

General Hierarchy of Evidence (simplified)
1. Level I (Strongest evidence):
• Systematic reviews & meta-analyses of randomized controlled trials (RCTs)
• High-quality RCTs with consistent results
2. Level II:
• Lesser-quality RCTs, prospective cohort studies
3. Level III:
• Case-control studies, retrospective cohorts
4. Level IV:
• Case series, case reports (no control group)
5. Level V (Weakest):
• Expert opinion, narrative reviews, lab/bench studies

In short: Level 1 = strongest proof, Level 5 = weakest.

Oxford CEBM Levels of Evidence (detailed clinical format)

Level 1 (Strongest)
• 1a: Systematic review of RCTs
• 1b: Individual RCT with narrow CI
• 1c: “All or none” evidence

Level 2
• 2a: Systematic review of cohort studies
• 2b: Individual cohort study / low-quality RCT
• 2c: Outcomes research, ecological studies

Level 3
• 3a: Systematic review of case-control studies
• 3b: Individual case-control study

Level 4
• Case series, poor-quality cohort/case-control

Level 5 (Weakest)
• Expert opinion, physiology/bench research

Clinical Use
• Level 1 → Grade A (strong recommendation)
• Level 2–3 → Grade B/C (moderate)
• Level 4–5 → Grade D (weak)

Example:
• New drug with meta-analysis of RCTs → Level 1a, Grade A.
• 10-patient case series → Level 4 evidence, weak.

Root idea.
The higher the level (1a, 1b) → the more reliable the evidence. The lower the level (4, 5) → the more cautious we must be in applying it.

ATOM-Amjad Taqweem online medicine

15/08/2025

12/08/2025

, also known as autism spectrum disorder ( ), is a neurodevelopmental condition characterized by differences or difficulties in and interaction, a preference for predictability and routine, sensory processing differences, focused interests, and repetitive behaviors. For a formal , these characteristics must cause clinically significant challenges greater than what is typical for a person's age and culture and must affect several areas of daily life. coordination difficulties are common but not required. Because is a , presentations vary and support needs range from minimal to being non-speaking or needing 24-hour care.